- Home
- MP vs BMRN Comparison
MP vs BMRN Comparison
Compare MP & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MP | BMRN |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.5B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | MP | BMRN |
|---|---|---|
| Price | $66.20 | $54.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 18 |
| Target Price | $73.91 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 5.0M | 1.5M |
| Earning Date | 05-07-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ 1.80 |
| Revenue | $331,952,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | $92.48 | $15.02 |
| Revenue Next Year | $63.75 | $12.23 |
| P/E Ratio | ★ N/A | $30.33 |
| Revenue Growth | ★ 147.15 | 17.62 |
| 52 Week Low | $18.64 | $50.76 |
| 52 Week High | $100.25 | $66.28 |
Technical Indicators
Market Signals| Indicator | MP | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 68.02 | 44.57 |
| Support Level | $65.20 | $51.77 |
| Resistance Level | $74.18 | $56.21 |
| Average True Range (ATR) | 2.94 | 1.40 |
| MACD | 1.75 | 0.02 |
| Stochastic Oscillator | 99.56 | 29.60 |
Price Performance
Historical ComparisonAbout MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.